Search Results
Results found for empty search
- We’re excited to announce our strategic partnership with Celtarys Research, a biotech company specializing in fluorescent ligand technologies and real-time, non-radioactive GPCR assays. This collaboration combines Dr. GPCR’s global platform with Celtarys’ innovative chemical biology tools, making it easier than ever for scientists to study ligand-receptor interactions, visualize binding, and accelerate drug discovery. We’re proud to welcome Celtarys to the Dr. GPCR ecosystem to support researchers worldwide and expand access to high-performance tools for GPCR-targeted therapeutics. ✳️Read the complete press release: https://www.ecosystem.drgpcr.com/post/dr-gpcr-and-celtarys-research-join-forces-to-expand-access-to-innovative-gpcr-tools #GPCR #DrGPCR #CeltarysResearch #DrugDiscoveryTools #FluorescentLigands #GPCRresearch #ScientificPartnership | Dr. GPCR Ecosystem
Home → Flash News → We’re excited to announce our strategic partnership with Celtarys Research, a biotech company specializing in fluorescent ligand technologies and real-time, non-radioactive GPCR assays. This collaboration combines Dr. GPCR’s global platform with Celtarys’ innovative chemical biology tools, making it easier than ever for scientists to study ligand-receptor interactions, visualize binding, and accelerate drug discovery. We’re proud to welcome Celtarys to the Dr. GPCR ecosystem to support researchers worldwide and expand access to high-performance tools for GPCR-targeted therapeutics. ✳️Read the complete press release: https://www.ecosystem.drgpcr.com/post/dr-gpcr-and-celtarys-research-join-forces-to-expand-access-to-innovative-gpcr-tools #GPCR #DrGPCR #CeltarysResearch #DrugDiscoveryTools #FluorescentLigands #GPCRresearch #ScientificPartnership Published on June 3, 2025 Category Celtarys - Media Partner We’re excited to announce our strategic partnership with Celtarys Research , a biotech company specializing in fluorescent ligand technologies and real-time, non-radioactive GPCR assays. This collaboration combines Dr. GPCR’s global platform with Celtarys’ innovative chemical biology tools , making it easier than ever for scientists to study ligand-receptor interactions, visualize binding, and accelerate drug discovery. We’re proud to welcome Celtarys to the Dr. GPCR ecosystem to support researchers worldwide and expand access to high-performance tools for GPCR-targeted therapeutics. ✳️ Read the complete press release: https://www.ecosystem.drgpcr.com/post/dr-gpcr-and-celtarys-research-join-forces-to-expand-access-to-innovative-gpcr-tools #GPCR #DrGPCR #CeltarysResearch #DrugDiscoveryTools #FluorescentLigands #GPCRresearch #ScientificPartnership Recent Articles Previous Next
- 🚨 Exciting Opportunity for Professionals in Drug Development! 🚨 Register today for a one-of-a-kind online course at Dr. GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 ⏰ Time: Thursdays, 10:00 AM - 11:30 AM (EST) This advanced course is essential for anyone working in drug development and focuses on: The essentials of new drug development Key pharmacokinetic elements (absorption, distribution, clearance) Hepatic metabolism and the Cytochrome P450 system Drug safety and toxicology (including drug-drug interactions) And much more! Gain deep insights into GPCR drug candidates and learn the critical assays and techniques required to bring therapeutic molecules to life. 🚨 Only 25 spots available — register now! 💡 This is a great opportunity for both academia and industry professionals. Sessions will be live, and you’ll also have 1:1 discussion time with the instructor. Full PDFs of the slides will be available! 🔗 https://buff.ly/lVEcRUc #GPCR #DrugDevelopment #Pharmacokinetics #TherapeuticDrugs #OnlineCourse #DrGPCRUniversity #PharmaceuticalIndustry | Dr. GPCR Ecosystem
Home → Flash News → 🚨 Exciting Opportunity for Professionals in Drug Development! 🚨 Register today for a one-of-a-kind online course at Dr. GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 ⏰ Time: Thursdays, 10:00 AM - 11:30 AM (EST) This advanced course is essential for anyone working in drug development and focuses on: The essentials of new drug development Key pharmacokinetic elements (absorption, distribution, clearance) Hepatic metabolism and the Cytochrome P450 system Drug safety and toxicology (including drug-drug interactions) And much more! Gain deep insights into GPCR drug candidates and learn the critical assays and techniques required to bring therapeutic molecules to life. 🚨 Only 25 spots available — register now! 💡 This is a great opportunity for both academia and industry professionals. Sessions will be live, and you’ll also have 1:1 discussion time with the instructor. Full PDFs of the slides will be available! 🔗 https://buff.ly/lVEcRUc #GPCR #DrugDevelopment #Pharmacokinetics #TherapeuticDrugs #OnlineCourse #DrGPCRUniversity #PharmaceuticalIndustry Published on March 12, 2025 Category Dr. GPCR Courses 🚨 Exciting Opportunity for Professionals in Drug Development! 🚨 Register today for a one-of-a-kind online course at Dr. GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 ⏰ Time: Thursdays, 10:00 AM - 11:30 AM (EST) This advanced course is essential for anyone working in drug development and focuses on: The essentials of new drug development Key pharmacokinetic elements (absorption, distribution, clearance) Hepatic metabolism and the Cytochrome P450 system Drug safety and toxicology (including drug-drug interactions) And much more! Gain deep insights into GPCR drug candidates and learn the critical assays and techniques required to bring therapeutic molecules to life. 🚨 Only 25 spots available — register now! 💡 This is a great opportunity for both academia and industry professionals. Sessions will be live, and you’ll also have 1:1 discussion time with the instructor. Full PDFs of the slides will be available! 🔗 https://buff.ly/lVEcRUc #GPCR #DrugDevelopment #Pharmacokinetics #TherapeuticDrugs #OnlineCourse #DrGPCRUniversity #PharmaceuticalIndustry Recent Articles Previous Next
- Think βCGRP is just αCGRP’s understudy? Think again. New research shows that βCGRP triggers distinct receptor signaling profiles across the CGRP receptor family, challenging the long-held assumption of redundancy. 🔬 A closer look reveals differences in G protein coupling, second messenger production, and receptor trafficking. 📊 This could reshape how we understand CGRP-related physiology—and how we target it in drug design. 🧠 Pain, inflammation, metabolism: the implications go far beyond signaling bias. 🔗 Read the full paper in Biochemistry: Unique Biased Agonism Profile of βCGRP on CGRP Family Receptors #GPCR #CGRP #DrugDiscovery #Pharmacology #SignalTransduction #Neuropeptides | Dr. GPCR Ecosystem
Home → Flash News → Think βCGRP is just αCGRP’s understudy? Think again. New research shows that βCGRP triggers distinct receptor signaling profiles across the CGRP receptor family, challenging the long-held assumption of redundancy. 🔬 A closer look reveals differences in G protein coupling, second messenger production, and receptor trafficking. 📊 This could reshape how we understand CGRP-related physiology—and how we target it in drug design. 🧠 Pain, inflammation, metabolism: the implications go far beyond signaling bias. 🔗 Read the full paper in Biochemistry: Unique Biased Agonism Profile of βCGRP on CGRP Family Receptors #GPCR #CGRP #DrugDiscovery #Pharmacology #SignalTransduction #Neuropeptides Published on June 16, 2025 Category GPCR Weekly News Think βCGRP is just αCGRP’s understudy? Think again. New research shows that βCGRP triggers distinct receptor signaling profiles across the CGRP receptor family, challenging the long-held assumption of redundancy. 🔬 A closer look reveals differences in G protein coupling, second messenger production, and receptor trafficking. 📊 This could reshape how we understand CGRP-related physiology—and how we target it in drug design. 🧠 Pain, inflammation, metabolism: the implications go far beyond signaling bias. 🔗 Read the full paper in Biochemistry : Unique Biased Agonism Profile of βCGRP on CGRP Family Receptors #GPCR #CGRP #DrugDiscovery #Pharmacology #SignalTransduction #Neuropeptides Recent Articles Previous Next
- This new study reveals how the conformation of parathyroid hormone (PTH) and the C-terminal helix α5 of Gα regulate the selective coupling of PTH1R to Gs or Gq. Through Cryo-EM and single-cell experiments, the authors show differences in binding affinity, duration, and strength. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/allosteric-mechanism-in-the-distinctive-coupling-of-gq-and-gs-to-the-parathyroid-hormone-type-1-receptor #gpcr #drgpcr | Dr. GPCR Ecosystem
Home → Flash News → This new study reveals how the conformation of parathyroid hormone (PTH) and the C-terminal helix α5 of Gα regulate the selective coupling of PTH1R to Gs or Gq. Through Cryo-EM and single-cell experiments, the authors show differences in binding affinity, duration, and strength. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/allosteric-mechanism-in-the-distinctive-coupling-of-gq-and-gs-to-the-parathyroid-hormone-type-1-receptor #gpcr #drgpcr Published on April 28, 2025 Category GPCR Weekly News This new study reveals how the conformation of parathyroid hormone (PTH) and the C-terminal helix α5 of Gα regulate the selective coupling of PTH1R to Gs or Gq. Through Cryo-EM and single-cell experiments, the authors show differences in binding affinity, duration, and strength. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/allosteric-mechanism-in-the-distinctive-coupling-of-gq-and-gs-to-the-parathyroid-hormone-type-1-receptor #gpcr #drgpcr Recent Articles Previous Next
- A high-resolution deep mutational scan of MC4R reveals how thousands of genetic variants impact obesity-linked signaling pathways and highlights new opportunities for precision drug discovery Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/high-resolution-deep-mutational-scanning-of-the-melanocortin-4-receptor-enables-target-characterization-for-drug-discovery #gpcr#drgpcr | Dr. GPCR Ecosystem
Home → Flash News → A high-resolution deep mutational scan of MC4R reveals how thousands of genetic variants impact obesity-linked signaling pathways and highlights new opportunities for precision drug discovery Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/high-resolution-deep-mutational-scanning-of-the-melanocortin-4-receptor-enables-target-characterization-for-drug-discovery #gpcr#drgpcr Published on May 5, 2025 Category GPCR Weekly News A high-resolution deep mutational scan of MC4R reveals how thousands of genetic variants impact obesity-linked signaling pathways and highlights new opportunities for precision drug discovery Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/high-resolution-deep-mutational-scanning-of-the-melanocortin-4-receptor-enables-target-characterization-for-drug-discovery #gpcr#drgpcr Recent Articles Previous Next
- Let’s connect the dots! Update your Dr. GPCR profile to make meaningful connections in the global GPCR network 🌐 ✳️Visit https://www.ecosystem.drgpcr.com/account/my-account and fill out the boxes with your most updated information. #gpcr #drgpcr | Dr. GPCR Ecosystem
Home → Flash News → Let’s connect the dots! Update your Dr. GPCR profile to make meaningful connections in the global GPCR network 🌐 ✳️Visit https://www.ecosystem.drgpcr.com/account/my-account and fill out the boxes with your most updated information. #gpcr #drgpcr Published on January 8, 2025 Category Dr. GPCR Profiles Let’s connect the dots! Update your Dr. GPCR profile to make meaningful connections in the global GPCR network 🌐 ✳️Visit https://www.ecosystem.drgpcr.com/account/my-account and fill out the boxes with your most updated information. #gpcr #drgpcr Recent Articles Previous Next
- irreversible drugs post 1 | Dr. GPCR Ecosystem
Discover how low-offset kinetics reshape drug efficacy. Join Terry’s Corner and master irreversible pharmacology for modern discovery programs. Home → Flash News → irreversible drugs post 1 Irreversible Drugs – Trailer Published on October 21, 2025 Category Terry's Corner Irreversible drugs change the rules of engagement. Unlike reversible ligands, their impact can persist long after the compound is gone — creating durable pharmacological effects that reshape how pharmacokinetics and pharmacodynamics intersect. In modern discovery programs, that’s a decisive advantage (or a hidden liability) in candidate selection. In this week’s lesson, you’ll unpack: Why low offset rates can mimic covalent effects without forming actual bonds. How target depletion and replenishment kinetics define the therapeutic window. How persistent binding alters structured tissue penetration — and why that matters for tumor targeting and beyond. These tactical frameworks are used to optimize molecules, sharpen PK/PD strategy, and mitigate downstream safety surprises before they appear in IND-enabling studies. Understanding irreversible interactions can mean the difference between a stalled program and a strategic breakthrough. Those who master kinetic pharmacology set the pace. 🟢 Join Terry’s Corner and sharpen your pharmacology toolkit. ✳️ Terry's Corner | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #DrugDiscovery #MedicinalChemistry #PKPD #ReceptorKinetics #DrugDevelopment Recent Articles Previous Next
- A casual postdoc in Santiago. A bold yes during the pandemic. Now? A biotech startup solving GPCR challenges worldwide 🌎 Celtarys Research didn’t follow the script, and neither does their chemistry. 🎧 In this week’s episode, Dr. Maria Majellaro talks about trusting your gut, learning to lead, and building science that scales. ✳️Celtarys is ready to support your assay development. Get to know more: Celtarys Research | Dr. GPCR Ecosystem | Dr. GPCR Ecosystem #GPCRtools #GPCRtrainingProgram #DrGPCR #BiotechLeadership | Dr. GPCR Ecosystem
Home → Flash News → A casual postdoc in Santiago. A bold yes during the pandemic. Now? A biotech startup solving GPCR challenges worldwide 🌎 Celtarys Research didn’t follow the script, and neither does their chemistry. 🎧 In this week’s episode, Dr. Maria Majellaro talks about trusting your gut, learning to lead, and building science that scales. ✳️Celtarys is ready to support your assay development. Get to know more: Celtarys Research | Dr. GPCR Ecosystem | Dr. GPCR Ecosystem #GPCRtools #GPCRtrainingProgram #DrGPCR #BiotechLeadership Published on June 17, 2025 Category Dr. GPCR Podcast A casual postdoc in Santiago. A bold yes during the pandemic. Now? A biotech startup solving GPCR challenges worldwide 🌎 Celtarys Research didn’t follow the script, and neither does their chemistry. 🎧 In this week’s episode, Dr. Maria Majellaro talks about trusting your gut, learning to lead, and building science that scales. ✳️Celtarys is ready to support your assay development. Get to know more: Celtarys Research | Dr. GPCR Ecosystem | Dr. GPCR Ecosystem #GPCRtools #GPCRtrainingProgram #DrGPCR #BiotechLeadership Recent Articles Previous Next
- Did you know that A2B adenosine receptor-triggered calcium mobilization varies by cell type? A recent study explores how Gi, Gq, Gs proteins, and PKC contribute differently to intracellular Ca²⁺ signaling, revealing a more complex regulation than previously thought. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/a2b-adenosine-receptor-triggered-intracellular-calcium-mobilization%3A-cell-type-dependent-involvement-of-gi%2C-gq%2C-gs-proteins-and-protein-kinase-c #gpcr #drgpcr #metabolism #obesity | Dr. GPCR Ecosystem
Home → Flash News → Did you know that A2B adenosine receptor-triggered calcium mobilization varies by cell type? A recent study explores how Gi, Gq, Gs proteins, and PKC contribute differently to intracellular Ca²⁺ signaling, revealing a more complex regulation than previously thought. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/a2b-adenosine-receptor-triggered-intracellular-calcium-mobilization%3A-cell-type-dependent-involvement-of-gi%2C-gq%2C-gs-proteins-and-protein-kinase-c #gpcr #drgpcr #metabolism #obesity Published on March 10, 2025 Category GPCR Weekly News Did you know that A2B adenosine receptor-triggered calcium mobilization varies by cell type ? A recent study explores how Gi, Gq, Gs proteins, and PKC contribute differently to intracellular Ca²⁺ signaling, revealing a more complex regulation than previously thought. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/a2b-adenosine-receptor-triggered-intracellular-calcium-mobilization%3A-cell-type-dependent-involvement-of-gi%2C-gq%2C-gs-proteins-and-protein-kinase-c #gpcr #drgpcr #metabolism #obesity Recent Articles Previous Next
- A newly engineered biosensor reveals DNAJC13 as a key player in GPCR trafficking, shedding light on its role in DOR downregulation and endosomal regulation. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/an-engineered-trafficking-biosensor-reveals-a-role-for-dnajc13-in-dor-downregulation #gpcr #drgpcr | Dr. GPCR Ecosystem
Home → Flash News → A newly engineered biosensor reveals DNAJC13 as a key player in GPCR trafficking, shedding light on its role in DOR downregulation and endosomal regulation. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/an-engineered-trafficking-biosensor-reveals-a-role-for-dnajc13-in-dor-downregulation #gpcr #drgpcr Published on March 24, 2025 Category GPCR Weekly News A newly engineered biosensor reveals DNAJC13 as a key player in GPCR trafficking, shedding light on its role in DOR downregulation and endosomal regulation. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/an-engineered-trafficking-biosensor-reveals-a-role-for-dnajc13-in-dor-downregulation #gpcr #drgpcr Recent Articles Previous Next
- New Episode Alert! 🎙️ Ep. 163 of the Dr. GPCR Podcast is here! 🚀 This time, we sit down with Dr. Dmitry Veprintsev to discuss the importance of asking the right GPCR questions. Whether you're a researcher, student, or GPCR enthusiast, this episode is packed with insights that will challenge how you think about your experiments. ✳️Tune in at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #DrGPCR #GPCRPodcast #Pharmacology #DrugDiscovery #Biotech #GPCRs | Dr. GPCR Ecosystem
Home → Flash News → New Episode Alert! 🎙️ Ep. 163 of the Dr. GPCR Podcast is here! 🚀 This time, we sit down with Dr. Dmitry Veprintsev to discuss the importance of asking the right GPCR questions. Whether you're a researcher, student, or GPCR enthusiast, this episode is packed with insights that will challenge how you think about your experiments. ✳️Tune in at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #DrGPCR #GPCRPodcast #Pharmacology #DrugDiscovery #Biotech #GPCRs Published on April 1, 2025 Category Dr. GPCR Podcast New Episode Alert! 🎙️ Ep. 163 of the Dr. GPCR Podcast is here! 🚀 This time, we sit down with Dr. Dmitry Veprintsev to discuss the importance of asking the right GPCR questions. Whether you're a researcher, student, or GPCR enthusiast, this episode is packed with insights that will challenge how you think about your experiments. ✳️Tune in at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #DrGPCR #GPCRPodcast #Pharmacology #DrugDiscovery #Biotech #GPCRs Recent Articles Previous Next
- Did you know? 🌟 Researchers have developed reversibly photoswitchable allosteric modulators for Class A GPCRs! 🧬💡 These innovative compounds, “Photo-BQCisA” and “Photo-BQCtrAns,” offer subtype-selective precision by combining allosteric modulation with light control, paving the way for new therapeutic strategies targeting muscarinic receptors (M1-M5). 🔬✨ Learn more about this breakthrough in the Ecosystem! | Dr. GPCR Ecosystem
Home → Flash News → Did you know? 🌟 Researchers have developed reversibly photoswitchable allosteric modulators for Class A GPCRs! 🧬💡 These innovative compounds, “Photo-BQCisA” and “Photo-BQCtrAns,” offer subtype-selective precision by combining allosteric modulation with light control, paving the way for new therapeutic strategies targeting muscarinic receptors (M1-M5). 🔬✨ Learn more about this breakthrough in the Ecosystem! Published on December 3, 2024 Category GPCR Weekly News Did you know? 🌟 Researchers have developed reversibly photoswitchable allosteric modulators for Class A GPCRs! 🧬💡 These innovative compounds, “Photo-BQCisA” and “Photo-BQCtrAns,” offer subtype-selective precision by combining allosteric modulation with light control, paving the way for new therapeutic strategies targeting muscarinic receptors (M1-M5). 🔬✨ Learn more about this breakthrough in the Ecosystem! ➡️ buff.ly/4fgX4ZH #gpcr #drgpcr Recent Articles Previous Next
- Courses by Terry | Dr. GPCR Ecosystem
Home Courses Articles About Log In / Sign Up Terry's Pharmacology Corner Lost in GPCR Complexity? Step Into Terry’s Corner Finally, See the Signal 🔥 Watch course | Oct 21, 2025 🔥 Watch course | Oct 14, 2025 🔥 Watch course | Oct 7, 2025 🔥 Watch course | Sept 30, 2025 🔥 Watch course | Sept 23, 2025 🔥 Watch course | Sept 16, 2025 🔥 Watch course | Sept 9, 2025 🔥 Watch course | Sept 2, 2025 🔥 Watch course | Aug 26, 2025 🔥 Watch course | Aug 19, 2025 🔥 Watch course | Aug 12, 2025 🔥 Watch course | Aug 5, 2025 🔥 Watch course | July 29, 2025 🔥 Watch course | July 22, 2025 🔥 Watch course | July 15, 2025 🔥 Watch course | July 8, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 TCBuyCourse Start Learning with Terry Best Value Terry’s Corner $2,999 $ 2,999 Every year Only Founders Get Discounted Full Vault Access —Then It’s Gone 40 years. One corner. One-time pricing. Valid until canceled 7 day free trial Select Watch 4 New Courses Each Month Connect in a Private Drug Hunter Hub Skip The Fluff, Learn What Matters Join Monthly AMAs with Terry Unlock 40+ Years of Expertise Master GPCRs with Precision Terry’s Pharmacology Corner — Created by Dr. Terry Kenakin , powered by Dr. GPCR . Stay connected on LinkedIn and YouTube . Explore : Foundational Lessons — Build Your Pharmacology Core Emerging Drug Hunter — Expand Your Edge Expert-Level Mastery — Advanced Pharmacology Live AMA Sessions with Terry
- Dr. GPCR University Vault | Dr. GPCR Ecosystem
Stay current in drug discovery with the University Vault. Quickly get up to speed on new GPCR targets and mechanisms, and gain a competitive edge with our extensive academic archive. University Vault: The Ultimate On-Demand GPCR Learning Library Every talk inside the University Vault represents years of research, collaboration, and innovation that continue to shape the GPCR field. Scientific breakthroughs don't expire! 200+ Expert Presentations 24/7 Access ∞ Rewatches Unlock the Vault Today! Filter & Explore Refine your experience with just three easy filters Select Category Select Event Select Format 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 ... 100 Become a Premium Member Less than $1/day 🔥 Upgrade to Premium Premium Yearly $249.99 $ 249.99 Every year 🚀 Everything you need to master GPCR science — in one membership. Valid until canceled Join Premium Now 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage 🚀 Don’t just keep up — lead the way. More Benefits What Scientists Appreciate The most comprehensive library of GPCR knowledge online. Period. Anonymous This looks super useful for drug discovery! The University Vault is a great way to keep up with academic progress and find new GPCR therapies. You can quickly learn about new targets and mechanisms, and it's an amazing competitive intelligence tool. Anonymous As a postdoc, my travel budget is limited. The University Vault gives me on-demand access to the talks I would have missed, keeping me at the cutting edge of the field. Being able to pause and re-watch complex presentations on signaling pathways has been crucial for advancing my own research. It’s the best professional development investment I’ve made. Anonymous Frequently Asked Questions University Vault Premium Pricing What is the University Vault? An exclusive, members-only archive of expert talks from past DrGPCR events, plus comprehensive courses and career resources. Who is it for? Researchers, scientists, postdocs, graduate students, and professionals in GPCR-related fields looking to advance their careers. Is the content still relevant? Absolutely. These presentations provide foundational and advanced insights that continue to inform current research, plus we continuously add new content. How often is new content added? New sessions are uploaded after each DrGPCR Summit or Symposia, plus we regularly add new courses, news, and update career resources. The Field is Evolving—Don't Fall Behind You don't need to attend every event to stay at the forefront of GPCR research. With the Vault, the knowledge comes to you—on demand, on your terms. Get Access Today!
- from rare earth probes to real internalization assays the ph sense story
Dr. Eric Trinquet discusses the science and story behind pH Sense, Revvity’s innovative GPCR internalization assay, and his journey in GPCR product R&D. Strategic Partners Dr. GPCR Podcast << Back to podcast list From Rare Earth Probes to Internalization Assays: The pHSense Story with Dr. Eric Trinquet What does it take to design a breakthrough GPCR assay—from idea to industrial impact? In this special episode, Dr. Eric Trinquet shares the inside story behind the development of pH Sense, Revvity’s latest innovation for tracking GPCR internalization. With a career spanning two decades at the intersection of fluorescence chemistry, functional assays, and product development, Eric takes us through the highs, failures, and scientific “aha” moments that shaped tools like the IP-One kit, Tag-lite, and now, pH Sense. If you’ve ever used HTRF or wondered what goes into making a product worthy of your next experiment, this is your backstage pass. You’ll hear what truly makes a reagent successful—and why academic–industry collaborations are essential for advancing GPCR research. ⸻ Inside This Episode How Eric and his team reimagined rare earth complexes to develop pH-sensitive probes with tunable brightness and lifetime. Why pH Sense enables high-throughput, no-wash tracking of GPCR internalization—even at endogenous expression levels. What shifted the team’s strategy from traditional calcium assays to IP1 accumulation—and why it mattered for Gq-coupled receptors. How collaborations with David Parker and Jean-Philippe Pin accelerated both probe chemistry and biological validation. What it felt like to see the first dose-response curves in native beta cells—and why that moment changed the trajectory of the project. Why the commercialization of a reagent is not the end, but the beginning of a feedback-driven innovation cycle. ⸻ Why It Might Hit Home If you’ve ever: Wrestled with unreliable endpoint assays or cumbersome radioactive protocols, Pushed for more physiologically relevant systems and hit the “overexpression ceiling,” Balanced scientific rigor with the unpredictability of product development, Or felt the thrill of seeing a tool you built drive real biological insight… …this episode will resonate. ⸻ About the Guest Dr. Eric Trinquet is Head of R&D for Life Sciences Reagents at Revvity, where he leads innovation in biochemical and cell-based assay platforms. With a foundational career at Cisbio Bioassays—later acquired by Revvity—Eric played a pivotal role in bringing technologies like HTRF, the IP-One kit, and the Tag-lite platform into widespread use. Originally trained as a physicist with a strong interest in photophysics and fluorescence chemistry, Eric transitioned into the GPCR field through hands-on assay development. His passion lies in turning cutting-edge probe chemistry into robust, scalable tools for drug discovery and basic research. What drives him? A mix of scientific curiosity, a tolerance for failure, and a commitment to delivering real-world impact—one product at a time. ⸻ More about Revvity pHSense Reagents GPCR Reagents Revvity on Dr. GPCR Dr. GPCR X Revvity Collaboration ⸻ Want more like this? Join the Dr. GPCR Premium Ecosystem for behind-the-scenes access to GPCR innovators, exclusive deep-dives, and practical tools to accelerate your research or career. 👥 Build connections. 🧪 Get insights. 🎧 Stay ahead. 👉 Join now Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Who we are | Dr. GPCR Ecosystem
Discover the mission, vision, and people behind the Dr. GPCR Ecosystem: uniting scientists, biotech, and innovators to advance GPCR research worldwide. Where GPCR Experts Move Science Forward Join the global community accelerating GPCR drug discovery through trusted insights, expert tools, and powerful connections. Join Free & Get Our Weekly News See Why it Matters 6,600+ followers 1,500+ Scientists 200+ Research Labs 50+ Biotech Companies Who We Are We are a global network of scientists, biotech innovators, pharma professionals, CRO leaders, and vendors—united by one mission: to make working on GPCRs easier, faster, and more collaborative. Dr. GPCR is both expert-led and community-first. We’re building together, with input from across the field. Built by Scientists. Driven by Impact. Dr. GPCR began as a podcast. Now, it's a global ecosystem of scientists, biotech teams, CRO leaders, and trainees working to move GPCR science forward—together. We created this space to make trusted knowledge and collaborations easier to access—without noise, fluff, or hype. What We Believe The Ecosystem was built with five key beliefs: Scientific rigor first This is a space for data-driven work, not hype. Usefulness over flash Every piece of content and feature must be practical. Transparency builds trust We're open about who we are and what we do. Collaboration is key Progress in GPCR science requires a collective effort. Inclusion matters We welcome diverse voices, experiences, and expertise. We designed the Ecosystem to support your work —no matter where you are in your GPCR journey. Our Journey (So Far) From the first podcast episode to a global platform, it's all built by and for the GPCR community. 2020 First Podcast Episode Launched our podcast to share expert insights with the scientific community. 2021 2nd Annual Summit Increased our reach and impact with the GPCR Community 2022 Community Platform Expanded beyond content to create a dedicated space for GPCR scientists to connect. 2023 First Symposium Inaugural Dr. GPCR Symposium with over 100 attendees 2024 GPCR University Launched comprehensive courses and expert talks to deepen scientific understanding. 2025 Terry's Corner & Consulting Launched our exclusive program with Dr. Kenakin and offered to CROs consulting services See Full Timeline The Field Is Growing—but Fragmented As GPCR scientists, we know the problem: too much noise, too little time, and nowhere to connect that's built for us. We built Dr. GPCR to: Curate relevant data—not overwhelm you with it Connect researchers with CROs, peers, and biotech leaders Provide high-quality tools and expert insights on demand Whether you're in a lab, launching a startup, or prepping for due diligence, we built this for you. The GPCR Challenge Scientists waste an average of 12 hours per week searching for relevant GPCR research and connections. Our ecosystem cuts that time by 80%. You'll Be in Good Company From PhDs to CRO execs to rising biotech founders—this is a vetted, mission-aligned community built to help you move faster. Premium Members Include: ✔ Drug hunters at early-stage biotechs ✔ CRO leaders building assays and tools ✔ Academic researchers moving into translational work ✔ Teams preparing for fundraising or due diligence Expert Contributors Include: ✔ Terry Kenakin, with his exclusive series on GPCR pharmacology ✔ Sam Hoare, simplifying GPCR data analysis ✔ Global CROs and biotech leaders, contributing behind-the-scenes tools and insight What Makes the Ecosystem Different Built for Drug Discovery Designed by scientists in the GPCR space to accelerate your research goals Collaborative by Design Connects researchers, CROs, and biotech teams—not just profiles, real relationships. Results-Driven Every tool and content block is built to help you make a decision or move forward. ✔ GPCR-specific content ✔ Expert curation ✔ Vetted community What Joining the Ecosystem Looks Like 1 Join Free Sign up in seconds. You'll instantly receive the GPCR Weekly News (free version). 2 Get Verified We manually review each profile to ensure trust and scientific relevance. 3 Start Exploring Browse free content, community updates, and learn what's available. 4 Upgrade Anytime Premium unlocks exclusive courses, community features, and deeper insights. Start Your Journey Today Meet the Leadership Founder & Director Yamina Berchiche Get in Touch Co-Founder Attila Foris Get in Touch Bussiness Manager Andreina Martin Get in Touch Executive Assistant Ivanna Rey Get in Touch Board Member Anne M. Quinn Get in Touch Board Member JoAnn Trejo Get in Touch Board Member Maria Waldhoer Get in Touch Chief Matchmaker Mark Schmeizl Get in Touch Why Upgrade to Premium Everyone who joins receives the free Weekly News. Premium gives you everything else—the full toolbox for moving science forward. Free Membership Includes: ✔ Free version of GPCR Weekly News - straight to your inbox! ✔ Select news and content ✔ Ecosystem and podcast updates Join Free Now Premium Members Unlock: ✔ Full Weekly News access – All GPCR papers, events, jobs + expert commentary ✔ Dr. GPCR University – 5 on-demand GPCR courses, 1 project management course, 200+ expert talks ✔ Community tools – Member directories, messaging, and forums Unlock Premium Access Partners Who Believe in the Mission Current Partner Partner Benefits Visibility to GPCR experts Direct connections Industry insights Explore Partnership Opportunities Ready to Join the Movement? Start free. Upgrade when you're ready. Dr. GPCR helps you stay ahead of the curve in science and strategy. Unlock Premium Access Join Free Now
- Ep 58 with Dr. Juan José Fung
Strategic Partners Dr. GPCR Podcast << Back to podcast list Dr. Juan José Fung About Dr. Juan José Fung Dr. Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused on targeting GPCR heteromers in cancer, headquartered in Seoul, Korea, with an R&D facility in the SF Bay Area. Dr. Fung received his Ph.D. from the Stanford University School of Medicine under the mentorship of Dr. Brian Kobilka , studying the dimerization of GPCRs. Dr. Fung continued his Postdoctoral training in Dr. Kobilka’s lab contributing to the elucidation of high-resolution structures of various GPCRs. Dr. Fung has spent significant time in the industry studying membrane proteins, antibodies, and HTS methods for drug discovery. His current work is mainly focused on screening and assay development to bridge the gap between in vitro and in vivo GPCR pharmacology. Dr. Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Ep 69 with Dr. Stephen Ferguson
Strategic Partners Dr. GPCR Podcast << Back to podcast list Dr. Stephen Ferguson The History of the Great Lakes GPCR Retreat with Dr. Stephen Ferguson About Dr. Stephen Ferguson Dr. Stephen Ferguson is a Professor in the Department of Cellular and Molecular Medicine at the University of Ottawa. He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr. Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994). He did his postdoctoral training with Dr. Marc G. Caron at Duke University (1994-1997), where he and his colleagues investigated the role of G protein-coupled receptor kinases and beta-arrestin in regulating G protein-coupled receptor endocytosis, trafficking, and signaling. He has held four Canada Research Chairs since 2001 and was previously a Heart and Stroke Foundation of Canada MacDonald Scholar (1998-2003) and Heart and Stroke Foundation of Ontario Career Investigator (2003-2016). He was a recipient of Canada's Top 40 under 40 award in 2004 and received Queen Elizabeth II, Diamond Jubilee Medal, in 2012. He has also received both Junior (2001) and Senior (2005) investigator awards from the Pharmacological Society of Canada. Most recently, in 2021, he was elected as a Fellow of the Canadian Academy of Health Science (FCAHS). His research career has focused on the investigation of the regulation of G protein-coupled receptors signaling mechanisms in health and disease. He currently holds multiple research grants from the Canadian Institutes of Health Research (CIHR) for his research investigating the role of metabotropic glutamate receptor signaling in Huntington’s and Alzheimer’s disease. Dr. Stephen Ferguson on the web Carlton University Canada Research Chairs Twitter ResearchGate LinkedIn Dr. GPCR Ecosystem Great Lakes GPCR Retreat on the web 21st Great Lakes GPCR Retreat More about previous GPCR Retreat meetings Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Ep 166 with Dr. Ben Clements
GPCR scientist Ben Clements shares how positive allosteric modulators could transform opioid therapy by boosting efficacy and reducing side effects. Strategic Partners Dr. GPCR Podcast << Back to podcast list When to Walk, When to Run: Lessons from the GPCR Trenches with Dr. Ben Clements 1. The Power of Inclusion in the GPCR Field This episode kicks off with a celebration of early-career scientists. Host Dr. Yamina Berchiche emphasizes the importance of diverse voices in the GPCR community: “It’s been a very difficult path to get more early-career scientists on the podcast. But it’s important to make your voice heard.” Benjamin Clements , a postdoctoral fellow at the University of Michigan, joins the conversation as a rising voice in GPCR pharmacology. His journey highlights the transition from general drug development to a deep dive into G protein-coupled receptors. 2. From Aspirations to Application: Ben’s Path into Science Ben shares his winding yet deliberate entry into science. Initially driven by a general passion for biology and a childhood dream of being an astronaut, he began with intestinal choline transport research at UNC. The realization that basic science could impact real patients was transformative. “It’s not just raw science — this can help someone at the end of the day.” – Ben Clements His pivot into neuroscience and pharmacology during grad school at the University of Minnesota laid the groundwork for his current work in GPCR pharmacology. 3. GPCRs and the Opioid Crisis: A New Pharmacological Frontier Now at the University of Michigan, Ben focuses on positive allosteric modulators (PAMs) targeting opioid receptors. The goal: maximize analgesia while minimizing side effects . “We’re enhancing the powerful pain-relieving effects of opioids while limiting respiratory depression, constipation, and abuse liability.” He is particularly excited by the novel application of PAMs in chronic and neuropathic pain models , including the neuroma model , which is typically opioid-insensitive. 4. Allosteric Modulation: The New Frontier of GPCR Drug Discovery Ben reflects on the emerging potential of allosteric modulation in GPCRs — a field that has lagged behind ion channels in clinical applications. “Allosteric modulation in GPCRs is so novel and so exciting. There’s so much availability, so much we don’t know yet.” By working with distinct chemical scaffolds like thiazolidines and xanthinediones, Ben is helping define how structurally different PAMs may act on similar receptor sites. 5. Scientific Rigor: The Value of ‘Old School’ Pharmacology Despite the availability of modern tools, Ben stresses the enduring value of classical methods like GTPγS assays , radioligand binding , and basic PK/PD models . “It doesn’t matter how many cool, fun tools you have. If you don’t understand the math that underlies an allosteric modulator, you won’t understand what’s happening.” This mindset keeps his science grounded, reproducible, and rooted in fundamentals. 6. Mentorship, Team Culture, and the Joy of Science Science is serious work, but Ben believes fun and collaboration fuel great outcomes. At Michigan, his lab balances rigor with light-hearted engagement — like daily squirrel trivia on their whiteboard. “Science is fun. We produce great data, but we also joke around. That’s how we work best.” Strong mentorship, open communication, and peer learning — especially from undergraduate trainees — shape his development as both a scientist and future educator. 7. Translating Discovery into Therapy: Bench to Bedside Vision Ben’s work seeks to merge in vitro mechanistic data with in vivo efficacy , guiding medicinal chemists toward creating druggable PAMs . “The goal is to smash all the amazing biology together and make a drug.” Using site-directed mutagenesis and pharmacological synergy assays , his team aims to understand how and where these compounds interact with the receptor, paving the way for structure-based drug design . 8. Structural Biology Roadblocks: The Cryo-EM Challenge One bottleneck in Ben’s work is visualizing binding sites of PAMs via cryo-EM , due to low compound potency and membrane-embedded binding pockets. “Our compounds don’t bind well enough to be seen clearly. That’s a real challenge with allosterics.” Still, by collaborating with structural biology teams and combining cryo-EM with NMR , his lab is narrowing down potential binding regions. 9. Lessons in Confidence, Collaboration, and Aha Moments From asserting himself as an undergrad to mastering unique techniques in grad school, Ben has accumulated key “aha” moments that shaped his confidence: Standing up to big names when safety was compromised. Realizing his technical skills were indispensable to the team. Discovering breakthrough results in neuroma pain models via a spontaneous collaboration. “We found something incredible — a tenfold shift in the methadone dose-response with our PAM.” 10. Advice for Junior Scientists: Read, Rest, Run Ben closes with wisdom for early-career researchers: “Academia is about knowing when to walk and when to run.” – Advice from Kelsey Flepsen He advocates: Reading one paper a day. Taking care of yourself when possible. Pushing hard when deadlines or breakthroughs demand it. “Your brain’s not a machine. Let it rest. That’s when the best ideas come — in the shower or on a walk.” Summary made with AI ________ Key Takeaway Episode 166 with Ben Clements is a deep dive into the pharmacological potential of GPCRs , the power of mentorship, and the mindset required to thrive in science. With clarity, curiosity, and a collaborative spirit, Ben reminds us that impactful science isn’t just about technology — it’s about people, persistence, and timing. “Science is all about knowing when to walk and knowing when to run.” Keyword Cloud GPCR research community , Dr. GPCR ecosystem , GPCR online course , GPCR scientist network , GPCR drug discovery , GPCR training program , G protein-coupled receptors , GPCR podcast , GPCR webinar series , GPCR data platform Summary created by AI About Ben Clements Dr. Ben M Clements is a behavioral pharmacologist who uses in vitro and in vivo models to discover and characterize novel treatments for chronic pain and opioid use disorder. He received his Ph.D. in Pharmaceutics from the University of Minnesota in 2022, studying the pharmacokinetics and pharmacodynamics of NMDA receptor antagonists. At the University of Michigan, Ben focuses on determining the mechanisms of action of a series of positive allosteric modulators of the mu-opioid receptor. This project involves molecular pharmacology in cell models to determine binding sites and mechanisms of allostery, as well as efficacy studies in mouse and rat models of acute and chronic pain. Dr. Clements' work is primarily focused on translational developments of small molecule therapeutics, and intends to apply these ideas to an independent academic laboratory. In addition, he plans to continue studying how neuromodulators, both exogenous and endogenous, can influence cellular activity, physiological behaviors, and human health. Ben Clements on the web University of Michigan X Google Scholar LinkedIn Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Ep 53 with Dr. Timo De Groof
Strategic Partners Dr. GPCR Podcast << Back to podcast list Dr. Timo De Groof About Dr. Timo De Groof Dr. Timo De Groof studied Biochemistry and Biotechnology at the University of Ghent where he graduated in 2015. During his master's studies, he specialized in Biomedical Biotechnology and Structural Biology/Biochemistry. During his last year of studies, Timo performed research in the biopharmaceutical company Argen X and gained experience in the identification and characterization of llama-derived antibodies in inflammatory diseases and oncology. From 2015 to 2019, he completed his Ph.D. in the Medicinal Chemistry group at VU University Amsterdam under the supervision of Prof. Dr. Martine Smit . During his Ph.D., Timo, together with Dr. Raimond Heukers , developed a nanobody platform within the research group and used this platform to develop nanobodies targeting viral G protein-coupled receptors with a special focus on the human cytomegalovirus-encoded chemokine receptor US28. During his Ph.D., he used these nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic potential in oncology and transplant infectious disease. Starting from September 2019, Timo started working as a postdoctoral researcher at the Vrije Universiteit Brussel in the In Vivo Cellular and Molecular Imaging (ICMI) group that is focused on translational/clinical applications of nanobodies. He currently is focusing on the development of nanobody-based immuno tracers as part of the IMI/EFPIA project entitled "Immune Image". Moreover, he is closely involved in multiple projects where he focuses on the generation of nanobodies against "difficult-to-target" proteins. In the near future, Timo hopes to combine his previous GPCR experience with his current focus to set up his own research line focusing on translational applications of GPCR-targeting nanobodies. Dr. Timo De Groof on the web LinkedIn Researchgate Twitter Medical Imaging Group Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Ep 94 with Dr. Brian Shoichet
Strategic Partners Dr. GPCR Podcast << Back to podcast list Brian Shoichet About Dr. Brian Shoichet BSc in Chemistry from MIT, Ph.D. with Tack Kuntz at UCSF; Postdoc with Brian Matthews in protein stability-activity tradeoffs, crystallography; started my independent lab at Northwestern University Medical School (1996) was recruited back to UCSF in 2003. Dr. Brian Shoichet on the web Google Scholar Shoichet Lab Twitter Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Ep 164 with Dr. Ian Chronis
Discover how GPR65 reshapes our understanding of GPCR signaling and its role in cancer, with Dr. Ian Chronis on the Dr. GPCR podcast. Strategic Partners Dr. GPCR Podcast << Back to podcast list Signals, pH, and Discovery : Cracking GPCR Mysteries with Dr. Ian Chronis In this episode, we welcome Dr. Ian Chronis, a recent Ph.D. graduate preparing to begin his postdoctoral work at the University of Michigan. Host Yamina Berchiche sets a welcoming tone as they dive into Ian’s unique academic journey—from early interests in medicine to his pivot toward pharmacology and GPCR research. His story offers valuable insights for anyone navigating the path from student to scientist. Ian discusses how his experiences at the University of Chicago and the University of Michigan shaped his scientific curiosity, particularly around G protein-coupled receptors (GPCRs) . His research centers on the beta-2 adrenergic receptor and GPR65 , a proton-sensing receptor with promising implications in cancer biology. He shares fascinating findings from his work on GPR65 , highlighting its unusual constitutive internalization and its ability to signal from acidic endosomes. This dual functionality—environmental sensing and compartment-specific signaling—offers a new layer of complexity in GPCR behavior. Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy, and how understanding receptor activity in acidic microenvironments could unlock new therapeutic strategies. Throughout the episode, Ian reflects on the value of a supportive lab culture , the need for better experimental tools in GPCR signaling , and the importance of engaging with the broader GPCR research community to drive innovation. The conversation wraps with a playful exchange about possible podcast titles, with Yamina suggesting "Ancient Greek Chemistry and GPCRs"—a nod to Ian’s heritage and the wide-ranging themes covered. This episode is both educational and inspiring, offering a behind-the-scenes look at a rising scientist’s journey in the ever-evolving world of GPCR research. Summary created by AI About Ian Chronis I recently finished my PhD in the lab of Dr. Manoj Puthenveedu at the University of Michigan, where I am now working as a postdoc. My research has looked at the trafficking and signaling of adrenergic and proton-sensing receptors, with specific focus on identifying novel regulatory proteins governing their function. Ian Chronis on the web LinkedIn Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Ep 49 with Dr. Sudha Shenoy
Strategic Partners Dr. GPCR Podcast << Back to podcast list Dr. Sudha Shenoy About Dr. Sudha Shenoy Dr. Sudha Shenoy is currently an Associate Professor in Medicine & Cell Biology in the Division of Cardiovascular Medicine, Duke University Medical Center. She received her Ph.D. from Oklahoma State University and completed her postdoctoral training with Dr. Robert J. Lefkowitz (Nobel Laureate, 2012) at Duke University. Dr. Shenoy’s postdoctoral research discovered that ubiquitination of mammalian G protein-coupled receptors is a tag for lysosomal degradation, whereas ubiquitination of the adaptor protein, β-arrestin, is a tag for receptor internalization and formation of signaling endosomes. Her laboratory has continued to work on identifying the molecular mechanisms that ascribe ubiquitin code on GPCRs and β-arrestins. Current efforts aim to understand the regulation of GPCR and beta-arrestin signaling in the heart and vascular endothelium by the deubiquitinating enzymes USP20 and USP33. Dr. Sudha Shenoy on the web Duke University Personal Reflections and Words of Wisdom: Story From Dr. Sudha Shenoy LinkedIn Pubmed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Ep 153 with Dr Jacek Mokrosiński
Strategic Partners Dr. GPCR Podcast << Back to podcast list Exploring Career Paths in GPCR Research with Dr. Jacek Mokrosiński About Dr. Jacek Mokrosiński "Jacek is a Senior Scientist at Novo Nordisk specializing in molecular pharmacology and cell-based screening technologies. He works in a multidisciplinary Chemical Biology team based at the recently established US R&D hub in Lexington, MA. Originally from Łódź, Poland, Jacek completed his Master's degree in Biology, specializing in Biochemistry at the University of Łódź. He then moved to Denmark, where he trained at the University of Copenhagen under supervision of Professor Thue W. Schwartz, and worked closely with Dr Birgitte Holst studying structural and mechanistic properties of ghrelin receptor and GPCRs involved in regulation of metabolism. After completing his Ph.D., he pursued research in genetics of metabolic regulation at the Institute of Metabolic Science - Metabolic Research Laboratories at the University of Cambridge in the team led by Professor I. Sadaf Farooqi. His research aimed at understanding molecular mechanism through which rare genetic variation may lead to or protecting from excessive body weight gain. As part of Farooqi's team, he characterized a series of novel human genetic variants identified in several GPCRs associated with obesity and other metabolic diseases, including GPR10, Melanocortin 4, Serotonin 2C and TRH receptors. Since 2021, Jacek has been working at Novo Nordisk at its research sites in the UK (Oxford) and the US (Indianapolis, Indiana and most recently Lexington, Massachusetts). He is passionate about cell-based in vitro technologies to study mechanistic properties of GPCRs and understanding the dynamics of receptor signalling. He is an avid proponent of close collaboration between industry and academia." Dr. Jacek Mokrosiński on the web ORCID ResearchGate LinkedIn Twitter Dr. GPCR AI Summary AI-generated content may be inaccurate or misleading. Always check for accuracy. Quick Recap Yamina and Jacek discussed their experiences with name mispronunciations, cultural differences, and the importance of a multidisciplinary approach in drug development. They also shared their career journeys, emphasizing the value of being open-minded, proactive, and embracing new opportunities. Lastly, they discussed their research interests, particularly in the field of GPCR, and the importance of method development, integrity, and honesty in scientific research. Next Steps Jacek will collaborate with Alex Romeo on a podcast about transitioning to the industry. In future talks and interviews, Jacek will share his stories and advice about GPCRs. Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. Summary Embracing Cultural Differences and Collaboration Yamina and Jacek shared their experiences with name mispronunciations and variations and discussed the importance of embracing cultural differences. They also discussed their professional backgrounds, highlighting the benefits of a multidisciplinary approach in drug development and the importance of collaboration between academia and industry. They talked about their shared passion for advancing science and improving patient outcomes, and their early interests in science and chemistry. They also shared their appreciation for documentaries showcasing manufacturing processes and the value of true experimentation in scientific research. Jacek's Career Journey and Advice Jacek and Yamina discussed Jacek's career journey, focusing on his experiences, challenges, and lessons learned. Jacek highlighted the importance of being open-minded and proactive, emphasizing that he learned by doing rather than taking specific courses. He also underscored the role of the people around him, expressing gratitude for their guidance and support. His advice was to be ready for changes and to embrace opportunities as they arise. Jacek's career path, which led him from Poland to Denmark and then to the US, exemplified his advice in action. Passion for Science and Career Journeys Yamina and Jacek discussed their passion for science and how it led them to their current careers. Jacek shared his experience of working with Piketa and how he found a job in Seda's lab at Cambridge, where he could immediately contribute due to his technical skills. Yamina agreed with Jacek's sentiments and spoke about her own journey, expressing her happiness in discussing science and reading papers. They emphasized the importance of finding a job that aligns with one's interests and strengths and being open to opportunities. They also highlighted the need for a work-life balance and the joy of a well-done job. Embracing Networking for Professional Growth Jacek and Yamina discussed the importance of building a network and being open to new opportunities. Jacek realized that being introverted doesn't mean he can't benefit from networking and interaction with others. He also highlighted the benefits of attending conferences and engaging with colleagues, sharing examples of how such interactions led to collaborations and new opportunities. Yamina agreed, emphasizing the importance of mental preparation and embracing different social situations, both virtual and in-person. They underscored the value of these interactions for professional growth and encouraged others to adopt a proactive approach to networking. Building Professional Connections Strategies Yamina and Jacek discussed the importance of building professional connections and strategies for introducing oneself to potential contacts. They emphasized the need to be mindful of the other person's time, provide clear explanations for the purpose of the connection, and offer something of value in return. They also highlighted the advantages of using LinkedIn as a tool for networking and the significance of personalizing messages to make a lasting impression. GPCR Research Interests and Collaborations Yamina and Jacek had a deep and engaging discussion about their research interests and achievements, particularly in the field of GPCR. Jacek shared his fascination with the growth hormone secretion receptor and the melanocortin 4 receptor, and their roles in regulating body weight and growth. Yamina, in turn, talked about her work on melanocortin receptors and an upcoming collaboration with a postdoc scientist. They also highlighted the importance of method development, integrity, and honesty in scientific research. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations. Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Ep 99 with Yamina Berchihce
Strategic Partners Dr. GPCR Podcast << Back to podcast list Dr. Yamina Berchiche About Dr. Yamina Berchiche Dr. Yamina A. Berchiche is the founder of Dr. GPCR, an ecosystem designed to bring together stakeholders interested in using G-Protein Coupled Receptors (GPCRs) that control virtually everything in the body as drug targets. The mission of Dr. GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the field and providing exposure to scientists through the Dr. GPCR podcast. Dr. Berchiche obtained her Master’s and Ph.D. in Biochemistry at the University of Montreal in Canada before training at Rockefeller University in New York and the National Institutes of Health in Bethesda, Maryland. She developed expertise over the past two decades studying structure/function relationships of GPCRs using live-cell bioluminescence resonance energy transfer (BRET). Her work focused on chemokine receptors, members of the GPCR family that control cell movement in the body. Dr. Yamina Berchiche on the web Website LinkedIn Facebook Twitter ResearchGate PubMed Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Ep 100 with Dr Caron Tribute Part 1
Strategic Partners Dr. GPCR Podcast << Back to podcast list Dr. Caron Tribute Part 1 About Marc Caron Dr. Caron and his family moved to Durham, NC in 1977, following receipt of his BSc in Chemistry from Laval University and his Ph.D. from the University of Miami. He joined the faculty of Laval University School of Medicine in 1975 and then returned to join Duke’s faculty, where he remained as a James B. Duke Professor until his death. He and his laboratory members studied the mechanisms of action and regulation of hormones and neurotransmitters and how they might underlie brain and behavior disorders such as schizophrenia, Parkinson's disease, attention-deficit hyperactivity disorder, mood disorders, and addiction. Among his many honors, Dr. Caron was an investigator of the Howard Hughes Medical Institute from 1992 to 2004, a member of the American Academy of Arts & Sciences, a fellow of the American Association for the Advancement of Science, and a recipient of the Julius Axelrod Award. An authoritative and prolific scientist, with over 650 scientific publications, he is most beloved as a mentor and his relentless encouragement that shaped the careers of hundreds of scientists worldwide. About our panelists in alphabetical order and the year they first met Dr. Caron Dr. Jeffrey Benovic (1985) Dr. Michel Bouvier (1985) Dr. Kathleen Caron - Co-host- (1970) Dr. Richard Cerione (1985) Dr. Brian Kolbilka (1987) Dr. Frederik Leeb-Lundberg (1984) Dr. Robert Lefkowitz (1973) Dr. Lee Limbird (1973) Dr. David Sibley (1988) Memories our panelists shared with us Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Ep 67 with Dr. Graham Ladds
Strategic Partners Dr. GPCR Podcast << Back to podcast list Dr. Graham Ladds About Dr. Graham Ladds Graham studied Biochemistry at the University of Birmingham before completing a Ph.D. in yeast pheromone signaling at Warwick. He continued to work at Warwick as a post-doc studying pro-hormone convertases before securing a 5-year independent fellowship funded through the NHS. This project enabled him to return to his interest in GPCRs. He progressed through the ranks at Warwick to become an Associate Professor before leaving in 2015 to join the Department of Pharmacology at Cambridge, where he is also a Fellow of St John’s College. In 2020, he was promoted to a Readership/Professor in Receptor Pharmacology and was elected a Fellow of the British Pharmacological Society. His research group uses a combination of pharmacological investigations and mathematical modeling to study factors that control agonist bias at GPCRs. These investigations have enabled him to foster strong collaborations with the pharmaceutical industry (GSK, Takada, and Firmenich) which have recently been enhanced through him being awarded a Royal Society Industry Fellowship to collaborate with AstraZeneca . Dr. Graham Ladds on the web Twitter ResearchGate LinkedIn Google Scholar PubMed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Ep 109 with Dr. Katarina Nemec
Strategic Partners Dr. GPCR Podcast << Back to podcast list Dr. Katarina Nemec About Dr. Katarina Nemec " I am a pharmacist with an interest in systems pharmacology and precision medicine. Since my undergraduate studies, I have been engaged in researching molecular mechanisms that govern human (patho-)physiology and their interplay with drugs. I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets to create drugs with fewer adverse effects. I studied Pharmacy at the University in Ljubljana, Slovenia, and at the University of Bonn, Germany, working initially on the role of prostaglandin receptor EP4 in chronic lymphocytic leukemia. During my PhD studies in Martin Lohse lab at the Max Delbrueck Center in Berlin, I consolidated my knowledge of GPCRs pharmacology while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically relevant GPCRs. In addition, I generated various optical biosensors based on fluorescence or bioluminescence resonance energy transfer technologies (FRET, BRET) that were used for functional screens with state-of-the-art microscopy and high throughput screening to explain novel ways of GPCR modulation. I am continuing with the development of advanced screening approaches in the Madan Babu lab to progress in the understanding of spatiotemporal regulation of biased GPCR activation and signaling. I want to combine experimental approaches with data-driven discovery and adopt data science methodology to tackle relevant scientific questions on the systems pharmacology level. " Dr. Katarina Nemec on the web Babu Lab ResearchGate Google Scholar ORCID LinkedIn Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Ep 122 with Dr. Nicolas Gilles
Strategic Partners Dr. GPCR Podcast << Back to podcast list Dr. Nicolas Gilles About Dr. Nicolas Gilles "Dr. Nicolas Gilles is an expert in the study of animal toxins. He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class. His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations, to in vivo validation. When the pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic development initiates through a dedicated start-up." Dr. Nicolas Gilles on the web Google Scholar LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution How a Failed Med School Dream Sparked a GPCR Biotech Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>
- Atypical Structure and Function of Typical Chemokine Receptors
Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Atypical Structure and Function of Typical Chemokine Receptors Date & Time Saturday, November 4th / 11:00 AM Abstract Coming Soon About Amy Ramsey "One of the principal efforts of our laboratory is to understand the physiological consequences of NMDA receptor deficiency using genetic mouse models. The NMDA receptor is a subtype of glutamate neurotransmitter receptor that regulates the formation and maintenance of synaptic connections between neurons. It plays an important role in the way that neurons wire together and change the strength of synaptic connections with experience. Our laboratory is interested in the role of NMDA receptors not only on neurons, but also on other cells of the brain such as astrocytes, oligodendrocytes, and endothelial cells. NMDA receptors are implicated in a number of brain disorders including schizophrenia, autism, and epilepsy. Our laboratory has a long-standing interest in the way that NMDA receptors contribute to the symptoms of schizophrenia. Recently, we have focused our efforts on GRIN disorder. This is a rare neurodevelopmental disorder caused by de novo mutations in the GRIN genes that encode NMDA receptors. Although symptoms of GRIN disorder appear very early in childhood, it can take years to reach the right diagnosis through genetic tests. Children with GRIN disorder experience developmental delays, intellectual impairment, visual impairments, and difficulties with daily tasks like talking and walking, feeding and toileting. Many children experience seizures that can be life-threatening. Our laboratory is working to help patients by developing genetically-modified mice that have disease-causing variants in their Grin1 gene. These mice can then be used to test dietary regimens, drugs, and adenoviral gene therapies for their ability to improve specific symptoms. The Ramsey lab uses a combination of biochemical and behavioural approaches to understand the many roles of NMDA receptors and to find treatments for debilitating brain disorders." The Ramsey Lab Amy Ramsey on the web University of Toronto Pubmed Google Scholar LinkedIn Twitter Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by